EXTON, PA — ProRx Pharma announced it has received a DEA Controlled Substances Registration Certificate, authorizing the company to handle and distribute select controlled substances. The certification marks a major step in expanding ProRx’s role as a provider of compliant, high-quality medications.
“Earning our DEA Controlled Substances Registration Certificate is a pivotal moment for ProRx,” said Kurt Lunkwitz, chief operating officer at ProRx. “It not only enables us to expand into compounding and distributing Schedule III substances like testosterone, but also demonstrates our commitment to regulatory excellence. This certification strengthens our ability to serve providers with trusted therapies, expand partnerships, and support long-term business growth.”
Schedule III substances, as defined under the Controlled Substances Act, carry a moderate to low risk of physical dependence or high psychological dependence. They have accepted medical use in the U.S. and pose less risk of abuse compared to Schedule I and II drugs.
The DEA certification authorizes ProRx to operate under strict federal requirements for security, recordkeeping, and accountability. In addition to DEA oversight, the company also maintains FDA 503B Outsourcing Facility Registration, state board of pharmacy licensure, and full cGMP compliance.
Together, these credentials reinforce ProRx’s regulatory framework and position the company to broaden its support for healthcare providers with therapies requiring the highest standards of safety and oversight.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.